Skip to content

The clinic investigation of the Chinese Patent Medicine Tongxinluo Capsule combine with Statins on the treatment of carotid plaque

The clinic investigation of the Chinese Patent Medicine Tongxinluo Capsule combine with Statins on the treatment of carotid plaque

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-14005367
Enrollment
Unknown
Registered
2014-06-17
Start date
2014-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

artherosclerosis

Interventions

Integrative group:Tongxinluo capsule+statins
Statins group:statins

Sponsors

Shandong Provincial Qianfoshan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Men and women aged 40 to 75 years old; 2. Noncalcified plaque are observed by ultrasound imaging technology; 3. The patient agreed to participate in the test, signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. With the history of percutaneous coronary intervention (PCI) or carotid endarterectomy; 2. With the history of recent myocardial infarction or apoplexy within half year; 3. Uncontrolled diabetes mellitus (fasting glucose greater than 7mmol/L), or hypertention(systolic blood pressure greater than 150mmHg and/or diastolic blood pressure greater than 90 mmHg); 4. Familial hypercholesterolemia; 5. Polyarteritis; 6.Pregnant or breast-feeding women, or women planning to become pregnant within one year, or women without effective contraceptive method in child bearing period; 7. Dysfunction of liver (relative index elevation, three times the upper limit of normal values of our laboratory), and kidney (the value of creatinine greater than 2 mg/dl); 8. Presence of other clinical condition, including repiratory disease, digestive disease, hematological disease, infection, immunologically mediated disease, endocrinic disease, neuropathy, psychotic disorders, neoplasms, or condition has risk to harm to the patients; 9. Reciept of any other investigational treatment of tranditional Chinese drug within 12 months prior to baseline visit.

Design outcomes

Primary

MeasureTime frame
IMT;FMD%;

Contacts

Public ContactRUI Xu
xuruicn@hotmail.com+86 15965311789

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026